Journal of Southern Medical University ›› 2024, Vol. 44 ›› Issue (5): 974-980.doi: 10.12122/j.issn.1673-4254.2024.05.20
• Clinical Research • Previous Articles Next Articles
Jingjing YANG1,2(), Lixia YIN3,4, Ting DUAN2,5, Minzhu NIU3, Zhendong HE2, Xinrui CHEN2, Xiaofeng ZHANG6,7, Jing LI4,7, Zhijun GENG6,7, Lugen ZUO1,7(
)
Received:
2024-03-22
Online:
2024-05-20
Published:
2024-06-06
Contact:
Lugen ZUO
E-mail:20231002102@stu.bbmc.edu.cn;zuolugen@126.com
Jingjing YANG, Lixia YIN, Ting DUAN, Minzhu NIU, Zhendong HE, Xinrui CHEN, Xiaofeng ZHANG, Jing LI, Zhijun GENG, Lugen ZUO. High expression of ATP5A1 in gastric carcinoma is correlated with a poor prognosis and enhanced glucose metabolism in tumor cells[J]. Journal of Southern Medical University, 2024, 44(5): 974-980.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.j-smu.com/EN/10.12122/j.issn.1673-4254.2024.05.20
Fig.1 ATP5A1 is overexpressed in gastric carcinoma tissues. A: Immunohistochemistry of ATP5A1 in gastric carcinoma and adjacent tissues. B: IOD values of ATP5A1 expression in gastric carcinoma and adjacent tissues. *P<0.05 vs adjacent tissue.
Factors | n | ATP5A1 expression (n, %) | χ2 | P | ||
---|---|---|---|---|---|---|
Low (n=57) | High (n=58) | |||||
Gender | Male | 85 | 42 (49.41%) | 43 (50.59%) | 0.003 | 0.956 |
Female | 30 | 15 (50.00%) | 15 (50.00%) | |||
Age (year) | <60 | 40 | 20 (50.00%) | 20 (50.00%) | 0.005 | 0.946 |
≥60 | 75 | 37 (49.33%) | 38 (50.67%) | |||
CEA (μg/L) | <5 | 54 | 35 (64.81%) | 19 (35.19%) | 9.470 | 0.002 |
≥5 | 61 | 22 (36.07%) | 39 (63.93%) | |||
CA19-9 (kU/L) | <37 | 55 | 38 (69.09%) | 17 (30.91%) | 16.077 | <0.001 |
≥37 | 60 | 19 (31.67%) | 41 (68.33%) | |||
Tumor size (cm) | <5 | 53 | 30 (56.60%) | 23 (43.40%) | 1.948 | 0.163 |
≥5 | 62 | 27 (43.55%) | 35 (56.45%) | |||
Pathological grading | G1-2 | 60 | 36 (60.00%) | 24 (40.00%) | 5.464 | 0.019 |
G3-4 | 55 | 21 (38.18%) | 34 (61.82%) | |||
Cancer cell type | Adenocarcinoma | 90 | 47 (52.22%) | 43 (47.78%) | 1.169 | 0.280 |
Other | 25 | 10 (40.00%) | 15 (60.00%) | |||
T stage | T1-T2 | 60 | 38 (63.33%) | 22 (36.67%) | 9.513 | 0.002 |
T3-T4 | 55 | 19 (34.55%) | 36 (65.45%) | |||
N stage | N0-N1 | 66 | 43 (65.15%) | 23 (34.85%) | 15.053 | <0.001 |
N2-N3 | 49 | 14 (28.57%) | 35 (71.43%) |
Tab.1 Clinical data of 115 patients with gastric carcinoma
Factors | n | ATP5A1 expression (n, %) | χ2 | P | ||
---|---|---|---|---|---|---|
Low (n=57) | High (n=58) | |||||
Gender | Male | 85 | 42 (49.41%) | 43 (50.59%) | 0.003 | 0.956 |
Female | 30 | 15 (50.00%) | 15 (50.00%) | |||
Age (year) | <60 | 40 | 20 (50.00%) | 20 (50.00%) | 0.005 | 0.946 |
≥60 | 75 | 37 (49.33%) | 38 (50.67%) | |||
CEA (μg/L) | <5 | 54 | 35 (64.81%) | 19 (35.19%) | 9.470 | 0.002 |
≥5 | 61 | 22 (36.07%) | 39 (63.93%) | |||
CA19-9 (kU/L) | <37 | 55 | 38 (69.09%) | 17 (30.91%) | 16.077 | <0.001 |
≥37 | 60 | 19 (31.67%) | 41 (68.33%) | |||
Tumor size (cm) | <5 | 53 | 30 (56.60%) | 23 (43.40%) | 1.948 | 0.163 |
≥5 | 62 | 27 (43.55%) | 35 (56.45%) | |||
Pathological grading | G1-2 | 60 | 36 (60.00%) | 24 (40.00%) | 5.464 | 0.019 |
G3-4 | 55 | 21 (38.18%) | 34 (61.82%) | |||
Cancer cell type | Adenocarcinoma | 90 | 47 (52.22%) | 43 (47.78%) | 1.169 | 0.280 |
Other | 25 | 10 (40.00%) | 15 (60.00%) | |||
T stage | T1-T2 | 60 | 38 (63.33%) | 22 (36.67%) | 9.513 | 0.002 |
T3-T4 | 55 | 19 (34.55%) | 36 (65.45%) | |||
N stage | N0-N1 | 66 | 43 (65.15%) | 23 (34.85%) | 15.053 | <0.001 |
N2-N3 | 49 | 14 (28.57%) | 35 (71.43%) |
Factors | Univariate analysis | Multivariate analysis | ||||
---|---|---|---|---|---|---|
Log-rank χ 2 | P | HR | 95% CI | P | ||
Gender (female vs male) | 1.436 | 0.231 | ||||
Age (≥60 year vs <60 year) | 0.745 | 0.388 | ||||
ATP5A1 expression (high vs low) | 30.968 | <0.001 | 2.771 | 1.458-5.267 | 0.002 | |
CEA (≥5 μg/L vs <5 μg/L) | 16.152 | <0.001 | 2.003 | 1.097-3.658 | 0.024 | |
CA19-9 (≥37 kU/L vs <37kU/L) | 35.142 | <0.001 | 3.348 | 1.666-6.728 | 0.001 | |
Tumor size (≥5 cm vs <5 cm) | 0.077 | 0.782 | ||||
Pathological grading (G3-G4 vs G1-G2) | 32.142 | <0.001 | 2.759 | 1.484-5.128 | 0.001 | |
Cancer cell type (adenocarcinoma vs other) | 1.251 | 0.263 | ||||
T stage (T3-T4 vs T1-T2) | 27.798 | <0.001 | 2.056 | 1.122-3.768 | 0.020 | |
N stage (N2-N3 vs N0-N1) | 28.006 | <0.001 | 2.251 | 1.211-4.187 | 0.010 |
Tab.2 Factors affecting postoperative survival of patients with gastric carcinoma
Factors | Univariate analysis | Multivariate analysis | ||||
---|---|---|---|---|---|---|
Log-rank χ 2 | P | HR | 95% CI | P | ||
Gender (female vs male) | 1.436 | 0.231 | ||||
Age (≥60 year vs <60 year) | 0.745 | 0.388 | ||||
ATP5A1 expression (high vs low) | 30.968 | <0.001 | 2.771 | 1.458-5.267 | 0.002 | |
CEA (≥5 μg/L vs <5 μg/L) | 16.152 | <0.001 | 2.003 | 1.097-3.658 | 0.024 | |
CA19-9 (≥37 kU/L vs <37kU/L) | 35.142 | <0.001 | 3.348 | 1.666-6.728 | 0.001 | |
Tumor size (≥5 cm vs <5 cm) | 0.077 | 0.782 | ||||
Pathological grading (G3-G4 vs G1-G2) | 32.142 | <0.001 | 2.759 | 1.484-5.128 | 0.001 | |
Cancer cell type (adenocarcinoma vs other) | 1.251 | 0.263 | ||||
T stage (T3-T4 vs T1-T2) | 27.798 | <0.001 | 2.056 | 1.122-3.768 | 0.020 | |
N stage (N2-N3 vs N0-N1) | 28.006 | <0.001 | 2.251 | 1.211-4.187 | 0.010 |
Fig.4 Overexpression of ATP5A1 accelerates glucose metabolism in gastric carcinoma cells. A, B: Western blotting for detecting ATP5A1 protein after lentivirus transfection. C, D: Glucose uptake and lactate production of the gastric cancer cells. E, F: Western blotting for the proteins related to glucose metabolism. *P<0.05 vs Control.
Fig.5 ATP5A1 promotes glucose metabolism by activating the JNK/JUN signaling pathway. A, B: Phosphorylation levels of JNK and JUN detected by Western blotting. C, D: Glucose uptake and lactate production in gastric cancer cells. E, F: Western blotting for detecting glucose metabolism-related protein expressions. *P<0.05 vs Control. #P<0.05 vs LV-ATP5A1.
Fig.6 Overexpression of ATP5A1 accelerates tumor growth and glucose metabolism in nude mice. A: Tumor xenografts in the 3 groups. B: Weight of the transplanted tumors. C: Volume of the transplanted tumors. D, E: Protein expressions of HK2, PFK1 and LDHA in xenografts detected by Western blotting. *P<0.05 vs Control.
1 | Smyth EC, Nilsson M, Grabsch HI, et al. Gastric cancer[J]. Lancet, 2020, 396(10251): 635-48. DOI: 10.1016/s0140-6736(20)31288-5 |
2 | Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-49. DOI: 10.3322/caac.21660 |
3 | Xia CF, Dong XS, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants[J]. Chin Med J, 2022, 135(5): 584-90. DOI: 10.1097/cm9.0000000000002108 |
4 | Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods[J]. Int J Cancer, 2019, 144(8): 1941-53. DOI: 10.1002/ijc.31937 |
5 | Zhang KC, Chen L. Chinese consensus on the diagnosis and treatment of gastric cancer with liver metastases[J]. Ther Adv Med Oncol, 2020, 12: 1758835920904803. DOI: 10.1177/1758835920904803 |
6 | Tan ZY. Recent advances in the surgical treatment of advanced gastric cancer: a review[J]. Med Sci Monit, 2019, 25: 3537-41. DOI: 10.12659/msm.916475 |
7 | Yang YQ, Ma YF, Xiang XY, et al. The prognostic value of the lymph node ratio for local advanced gastric cancer patients with intensity-modulated radiation therapy and concurrent chemotherapy after radical gastrectomy in China[J]. Radiat Oncol, 2020, 15(1): 237. DOI: 10.1186/s13014-020-01687-0 |
8 | Nakayama I, Takahari D. The role of angiogenesis targeted therapies in metastatic advanced gastric cancer: a narrative review[J]. J Clin Med, 2023, 12(9): 3226. DOI: 10.3390/jcm12093226 |
9 | Lin JX, Lian NZ, Gao YX, et al. m6A methylation mediates LHPP acetylation as a tumour aerobic glycolysis suppressor to improve the prognosis of gastric cancer[J]. Cell Death Dis, 2022, 13(5): 463. DOI: 10.1038/s41419-022-04859-w |
10 | Zhao HY, Jiang RK, Feng ZJ, et al. Transcription factor LHX9 (LIM Homeobox 9) enhances pyruvate kinase PKM2 activity to induce glycolytic metabolic reprogramming in cancer stem cells, promoting gastric cancer progression[J]. J Transl Med, 2023, 21(1): 833. DOI: 10.1186/s12967-023-04658-7 |
11 | Pouysségur J, Marchiq I, Parks SK, et al. ‘Warburg effect' controls tumor growth, bacterial, viral infections and immunity-Genetic deconstruction and therapeutic perspectives[J]. Semin Cancer Biol, 2022, 86(Pt 2): 334-46. DOI: 10.1016/j.semcancer.2022.07.004 |
12 | Jonckheere AI, Smeitink JAM, Rodenburg RJT. Mitochondrial ATP synthase: architecture, function and pathology[J]. J Inherit Metab Dis, 2012, 35(2): 211-25. DOI: 10.1007/s10545-011-9382-9 |
13 | Jana S, Heaven MR, Stauft CB, et al. HIF-1α-dependent metabolic reprogramming, oxidative stress, and bioenergetic dysfunction in SARS-CoV-2-infected hamsters[J]. Int J Mol Sci, 2022, 24(1): 558. DOI: 10.3390/ijms24010558 |
14 | Li JB, Wang JZ, Pan TH, et al. USP25 deficiency promotes T cell dysfunction and transplant acceptance via mitochondrial dynamics[J]. Int Immunopharmacol, 2023, 117: 109917. DOI: 10.1016/j.intimp.2023.109917 |
15 | 梁亚敏. TET2/ATP5A1在低剪切应力诱导内皮间质转化中的作用及机制研究[D]. 衡阳: 南华大学, 2022. |
16 | Ba YS, Ma FW, Ma YW, et al. ATP5A1 participates in transcriptional and posttranscriptional regulation of cancer-associated genes by modulating their expression and alternative splicing profiles in HeLa cells[J]. Technol Cancer Res Treat, 2021, 20: 15330338211039126. DOI: 10.1177/15330338211039126 |
17 | Pan J, Sun LC, Tao YF, et al. ATP synthase ecto-α-subunit: a novel therapeutic target for breast cancer[J]. J Transl Med, 2011, 9: 211. DOI: 10.1186/1479-5876-9-211 |
18 | 杨素丽. ATP5A1在大肠癌中的表达及其临床意义[D]. 长春: 吉林大学, 2017. |
19 | Li M, Wang M, Xi Y, et al. Isolation and identification of a Tibetan pig porcine epidemic diarrhoea virus strain and its biological effects on IPEC-J2 cells[J]. Int J Mol Sci, 2024, 25(4): 2200. DOI: 10.3390/ijms25042200 |
20 | Choi Y, Park J, Choi Y, et al. C-Jun N-terminal kinase activation has a prognostic implication and is negatively associated with FOXO1 activation in gastric cancer[J]. BMC Gastroenterol, 2016, 16(1): 59. DOI: 10.1186/s12876-016-0473-9 |
21 | Zhang L, Gao YG. ICOSLG acts as an oncogene to promote glycolysis, proliferation, migration, and invasion in gastric cancer cells[J]. Arch Biochem Biophys, 2024, 752: 109841. DOI: 10.1016/j.abb.2023.109841 |
22 | Peng CZ, Yang X, Li X, et al. ALDOB plays a tumor-suppressive role by inhibiting AKT activation in gastric cancer[J]. J Cancer, 2023, 14(12): 2255-62. DOI: 10.7150/jca.83456 |
23 | Xu GY, Li JY. ATP5A1 and ATP5B are highly expressed in glioblastoma tumor cells and endothelial cells of microvascular proliferation[J]. J Neurooncol, 2016, 126(3): 405-13. DOI: 10.1007/s11060-015-1984-x |
24 | Yuan LS, Chen L, Qian KY, et al. A novel correlation between ATP5A1 gene expression and progression of human clear cell renal cell carcinoma identified by co-expression analysis[J]. Oncol Rep, 2018, 39(2): 525-36. |
25 | Martínez-Esquivias F, Gutiérrez-Angulo M, Becerra-Ruiz JS, et al. Bioinformatic analysis of the effect of silver nanoparticles on colorectal cancer cell line[J]. Biomed Res Int, 2022, 2022: 6828837. DOI: 10.1155/2022/6828837 |
26 | Zhang GF, Zhong JM, Lin L, et al. Loss of ATP5A1 enhances proliferation and predicts poor prognosis of colon adenocarcinoma[J]. Pathol Res Pract, 2022, 230: 153679. DOI: 10.1016/j.prp.2021.153679 |
27 | Bose S, Zhang C, Le A. Glucose metabolism in cancer: the Warburg effect and beyond[J]. Adv Exp Med Biol, 2021, 1311: 3-15. DOI: 10.1007/978-3-030-65768-0_1 |
28 | Liberti MV, Locasale JW. The Warburg effect: how does it benefit cancer cells?[J]. Trends Biochem Sci, 2016, 41(3): 211-8. DOI: 10.1016/j.tibs.2015.12.001 |
29 | Yang HL, Lin PY, Vadivalagan C, et al. Coenzyme Q0 defeats NLRP3-mediated inflammation, EMT/metastasis, and Warburg effects by inhibiting HIF-1α expression in human triple-negative breast cancer cells[J]. Arch Toxicol, 2023, 97(4): 1047-68. DOI: 10.1007/s00204-023-03456-w |
30 | Mi YS, Li QH, Liu BT, et al. Ubiquitous mitochondrial creatine kinase promotes the progression of gastric cancer through a JNK-MAPK/JUN/HK2 axis regulated glycolysis[J]. Gastric Cancer, 2023, 26(1): 69-81. DOI: 10.1007/s10120-022-01340-7 |
[1] | Yan WANG, Yuqing RUAN, Can CUI, Xiu WANG. Jiaotaiwan improves brain glucose metabolism in a mouse model of Alzheimer's disease by activating the PI3K/AKT signaling pathway [J]. Journal of Southern Medical University, 2024, 44(5): 894-903. |
[2] | SHEN Mengdi, ZHAO Na, DENG Xiaojing, DENG Min. High expression of COX6B2 in gastric cancer is associated with poor long-term prognosis and promotes cell proliferation and cell cycle progression by inhibiting p53 signaling [J]. Journal of Southern Medical University, 2024, 44(2): 289-297. |
[3] | ZHANG Nuo, ZHANG Zhen, ZHANG Yulu, SONG Xue, ZHANG Xiaofeng, LI Jing, ZUO Lugen, HU Jianguo. PCID2 is highly expressed in gastric cancer and affects the prognosis by regulating cancer cell cycle and proliferation [J]. Journal of Southern Medical University, 2024, 44(2): 324-332. |
[4] | ZHANG Wenjing, ZHANG Nuo, YANG Zi, ZHANG Xiaofeng, SUN Aofei, WANG Lian, SONG Xue, GENG Zhijun, LI Jing, HU Jianguo. Overexpression of BZW1 promotes invasion and metastasis of gastric cancer cells by regulating Wnt/β-catenin signaling and promoting epithelial-mesenchymal transition [J]. Journal of Southern Medical University, 2024, 44(2): 354-362. |
[5] | DUAN Ting, ZHANG Zhen, SHI Jinran, XIAO Linyu, YANG Jingjing, YIN Lixia, ZHANG Xiaofeng, GENG Zhijun, LU Guoyu. High expression of CPNE3 correlates with poor long-term prognosis of gastric cancer by inhibiting cell apoptosis via activating PI3K/AKT signaling [J]. Journal of Southern Medical University, 2024, 44(1): 129-137. |
[6] | YAO Yina, LIU Jia, ZHOU Xiangjun, LIU Zeyu, QIU Shizhen, HE Yingzheng, ZHOU Xueqiong. A pan-cancer analysis of TTC9A expression level and its correlation with prognosis and immune microenvironment [J]. Journal of Southern Medical University, 2024, 44(1): 70-82. |
[7] | WANG Lian, XIA Yongsheng, ZHANG Zhen, LIU Xinyue, SHI Jinran, WANG Yueyue, LI Jing, ZHNAG Xiaofeng, GENG Zhijun, SONG Xue, ZUO Lugen. High expression of MRPL13 promotes cell cycle progression and proliferation of gastric cancer cells by inhibiting p53 signaling to affect long-term prognosis [J]. Journal of Southern Medical University, 2023, 43(9): 1558-1566. |
[8] | ZUO Lugen, WANG Lian, YANG Zi, LI Junjie, WANG Wenfeng, LI Jing, WANG Yueyue, SONG Xue, ZHNAG Xiaofeng, GENG Zhijun. High expression of CAMSAP2 promotes invasion and metastasis of gastric cancer cells by upregulating TGF-β signaling [J]. Journal of Southern Medical University, 2023, 43(9): 1460-1468. |
[9] | CAO Danping, CAI Juan, LI Yanna, DONG Runyu, WANG Zhixiong, ZUO Xueliang. TMEM64 is highly expressed in hepatocellular carcinoma and promotes tumor cell proliferation and invasion [J]. Journal of Southern Medical University, 2023, 43(8): 1345-1355. |
[10] | WANG Qiusheng, ZHANG Zhen, WANG Lian, WANG Yu, YAO Xinyu, WANG Yueyue, ZHANG Xiaofeng, GE Sitang, ZUO Lugen. High expression of death-associated protein 5 promotes glucose metabolism in gastric cancer cells and correlates with poor survival outcomes [J]. Journal of Southern Medical University, 2023, 43(7): 1063-1070. |
[11] | ZHANG Hao, ZHANG Zhen, WANG Qiusheng, WANG Lian, YANG Zi, GENG Zhijun, WANG Yueyue, LI Jing, ZUO Lugen. FJX1 overexpression is associated with poor prognosis and promotes gastric cancer proliferation via the PI3K/AKT signaling pathway [J]. Journal of Southern Medical University, 2023, 43(6): 975-984. |
[12] | CAI Taonong, LU Jiangli, LIN Zhijun, LUP Mingrui, LIANG Haitao, QIN Zike, YE Yunlin. Intravesical instillation of bacillus Calmette-Guerin for non-muscle invasive bladder cancer: outcomes of 421 patients in a single center [J]. Journal of Southern Medical University, 2023, 43(3): 488-494. |
[13] | ZHANG Benlong, LU Yixun, LI Li, GAO Yunhe, LIANG Wenquan, XI Hongqing, WANG Xinxin, ZHANG Kecheng, CHEN Lin. Establishment and validation of a nomogram for predicting prognosis of gastric neuroendocrine neoplasms based on data from 490 cases in a single center [J]. Journal of Southern Medical University, 2023, 43(2): 183-190. |
[14] | TANG Qiao, ZHOU Chao, ZHANG Ning, HE Zhaoyun, ZHANG Jingjing, FU Shuangnan, LI Xin, LIU Pengcheng, ZHANG Tianyi, ZHANG Jin, GONG Man. Prognosis and risk factors for mortality in cirrhotic patients with probable spontaneous bacterial peritonitis [J]. Journal of Southern Medical University, 2023, 43(12): 2043-2052. |
[15] | SU Lili, LIANG Wanqing, LÜ Zhenyu, HAN Xiao. PLXNA1 is highly expressed in hepatocellular carcinoma and affects patients' survival and immune microenvironment [J]. Journal of Southern Medical University, 2023, 43(11): 1909-1918. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||